Lucid Capital has initiated coverage of Polaryx Therapeutics plc with a 'buy' rating, pointing to the company's pipeline of rare disease therapies as a key driver of future value. The investment bank's analysts believe Polaryx's lead drug candidate, which targets a rare genetic condition currently lacking approved treatments, could capture a significant share of a market estimated to be worth billions globally. The news sent shares in the London-listed biotech firm up 3.2% to 472p in early trading on Monday.
The initiation comes amid a broader resurgence of interest in UK biotechnology stocks, particularly those focused on orphan drug development. Polaryx, which listed on the FTSE 250 in 2024, has been advancing its flagship therapy through Phase II trials, with interim data expected later this year. Lucid Capital's report notes that the company's robust intellectual property portfolio and strategic partnerships with academic institutions provide a solid foundation for long-term growth.
For UK investors, the rating adds another name to a growing list of specialist healthcare plays. The FTSE 250 index edged up 0.4% on the day, with the healthcare sector outperforming. Analysts at Lucid Capital emphasised that Polaryx's focus on diseases with high unmet medical needs reduces regulatory risk and opens the door to accelerated approval pathways. 'The rare disease space offers premium valuations for successful therapies, and Polaryx is well-positioned to deliver,' the note stated.
However, the biotech sector remains volatile, and Polaryx faces competition from larger pharmaceutical companies exploring similar genetic targets. The company's cash runway extends into late 2027, according to its most recent annual report, but further financing may be required to fund late-stage trials. Market observers note that positive trial results would likely trigger a re-rating, while setbacks could see the stock retreat sharply.
For UK pension holders with exposure to growth-focused funds, the development underscores the importance of diversification within healthcare allocations. While Polaryx represents a high-risk, high-reward opportunity, its inclusion in broader biotech indices means that even passive investors have indirect exposure to its performance. The FTSE All-Share index remained flat on the day, with the healthcare sector contributing 0.1 percentage points to its overall performance.